ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ERBB2-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ERBB2-inhibitor
12
trial(s) found.
NCT07195695
Curative
Phase 3
Recruiting
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations (
1479-0032
)
ERBB2 inhibitor,second generation
Non-small cell lung cancer
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06897735
Advanced
Phase 1
Not yet recruiting
A Phase I Pilot Study to Evaluate the Bioequivalence, Pharmacokinetics, and Safety of Inhaled Afatinib Dimaleate Compared to the Reference Oral Afatinib Dimaleate in Healthy Smoking Volunteers (
EDDIS-a1
)
EGFR inhibitor,second generation
ERBB2 inhibitor,second generation
Cancer
Lung cancer
Melanoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06816992
Advanced
Phase 1
Recruiting
Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC (
ORIC-114-05
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
bispecific cMET/EGFR antibody
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06806982
Advanced
Phase 1
Recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VRN101099 in Patients With HER2-Positive Solid Tumors (
VRN101099-01
)
ERBB2 inhibitor,second generation
HER2-positive solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Gastroesophageal cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06521554
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) (
NVL-330-01
)
ERBB2 inhibitor,exon 20 selective
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - Saint Leonards - North Shore Health Hub
NCT06452277
Advanced
Phase 3
Recruiting
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations (
SOHO-02
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Non-small cell lung cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
+ ERBB2 inhibitor
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06151574
Advanced
Phase 3
Recruiting
Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations (
1479-0008
)
ERBB2 inhibitor,second generation
Non-small cell lung cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05315700
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (
ORIC-114-01
)
EGFR inhibitor,exon 20 selective
ERBB2 inhibitor,exon 20 selective
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12620000583943
Advanced
Phase 1 / Phase 2
Recruiting
An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. (
EOHC-1001-01
)
EGFR inhibitor,second generation
ERBB2 inhibitor,second generation
Cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Not yet recruiting (1)
Recruitment Country and State
VIC (7)
NSW (7)
WA (4)
QLD (4)
NZ (1)
SA (1)
ACT (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (4)
Trial Type
Advanced (11)
Curative (1)
Cancer Therapy Class
ERBB2
100%
EGFR
50%
PD-1
25%
PD-1/PD-L1
25%
PD-L1
8%
MET
8%
VEGF
8%
Facility
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2065 - Saint Leonards - North Shore Health Hub (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2605 - Garran - The Canberra Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NA
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
6009 - Nedlands - One Clinical Research (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3168 - Clayton - Monash Medical Centre (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Gastrointestinal cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Melanoma
HER2-positive solid tumour
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
Breast adenocarcinoma
Breast cancer
HER2-low breast cancer
HER2-negative breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy